2016年<\/span>全球有超19亿成年人超重（定义为身体质量指数（BMI）≥25^{2<\/sup>），其中超6.5亿人为肥胖（定义为BMI≥30^{3<\/sup>）。世界肥胖联合会预测，到2025年，可能有27亿成年人超重或肥胖，这将成为全球健康挑战，也给个人、医疗保健系统和社会带来沉重的负担。超重和肥胖是复杂的慢性疾病，涉及异常或过多的脂肪堆积，可对个人的整体健康构成风险。^{4<\/sup><\/p> \n}}}

Survodutide 是一种GCGR\/GLP-1R双重激动剂，可同时激活胰高血糖素样肽-1（ GLP-1 ）受体和胰高血糖素（GCG）受体，这对于控制代谢功能至关重要^{5<\/sup>。在另一项II期研究中评估了survodutide对NASH和肝纤维化（F1\/F2\/F3期）成人患者（无论是否患有2型糖尿病）的治疗效果^{6<\/sup>，该研究获得了美国FDA的快速通道认定^{7<\/sup>。Survodutide由勃林格殷格翰和Zealand Pharma联合开发，是勃林格殷格翰在代谢心肾疾病领域研发组合的组成部分。<\/p> \n}}}

勃林格殷格翰致力于研究突破性疗法，旨在变革生命，守护世世代代的健康。作为一家研发驱动的全球领先生物制药企业，公司在医疗需求高度未得到满足的领域通过创新展现价值。勃林格殷格翰自1885年成立以来一直是一家独立的家族企业，始终着眼长远与可持续发展。在人用药品、动物保健两大业务领域，全球有超过5.3万名员工服务逾130个地区。更多详情，请访问：www.boehringer-ingelheim.com<\/a><\/p> \n

\n \n \n \n \n \n \n \n \n \n
1.Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide (BI 456906). Available at https:\/\/www.boehringer-ingelheim.com\/human-health\/metabolic-diseases\/obesity\/phase-ii-clinical-trial-weight-loss-results.<\/span><\/p> <\/td> \n <\/tr> \n
2.World Health Organization. Obesity and Overweight. Available at: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight. Accessed June 2023.<\/span><\/p> <\/td> \n <\/tr> \n
3.World Heart Federation. Obesity. 2015. Available at: https:\/\/world-heart-federation.org\/what-we-do\/obesity\/#:~:text=Global%20estimates%20suggest%20that%20almost,overweight%20or%20obesity%20by%202025 . Accessed June 2023.<\/span><\/p> <\/td> \n <\/tr> \n
4.Bray GA et al. Obesity: A chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev 2017;18:715–723.<\/span><\/p> <\/td> \n <\/tr> \n
5.T. Zimmerman et al. BI 456906: Discovery and preclinical pharmacology of a novel GCGR\/GLP-1R dual agonist with robust anti-obesity efficacy. Molecular Metabolism. 2022;66:101633.<\/span><\/p> <\/td> \n <\/tr> \n
6.ClinicalTrials.gov: A Study to Test Safety and Efficacy of BI456906 in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3). Available at https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04771273https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04771273 Accessed June 2023.<\/span><\/p> <\/td> \n <\/tr> \n
7.Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH. https:\/\/www.boehringer-ingelheim.com\/us\/press-release\/boehringer-ingelheim-and-zealand-pharma-receive-fda-fast-track-designation. Accessed June 2023.<\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n
<\/p>"]; $("#dvExtra").html(content_array[0]);})();